PARSIPPANY, N.J., Oct. 21, 2011 /PRNewswire/ -- Approximately 100 cherry tree saplings were planted in Central Park of Morris County today, the newest park in the Morris County Park System, located in Parsippany Troy-Hills. The planting will create Cherry Lane and celebrate the 100th anniversary of the historic gift ... read more

PARSIPPANY, N.J., Sept. 8, 2011 /PRNewswire/ -- Some of the most enjoyable family moments are spent over a meal. Whether it's a celebration, or a typical weeknight dinner, your favorite family recipe can bring loved ones together. However, if you happen to be one of the more than 12 million ... read more

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- With the US Food and Drug Administration (FDA) approval today of Zelboraf(TM) (vemurafenib), a first-in-class personalized treatment for patients with unresectable (inoperable) or metastatic melanoma with a BRAF V600E mutation as detected by an FDA-approved test, Daiichi Sankyo prepares to enter the US ... read more

PARSIPPANY, N.J., Aug. 17, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. announced that Mahmoud Ghazzi, MD, PhD has joined Daiichi Sankyo Pharma Development (DSPD) as its new executive vice president of drug development for the Americas region. DSPD, headquartered in Edison, NJ, is responsible for the regional delivery of global clinical ... read more

PARSIPPANY, NJ -- (Marketwire) -- 05/03/10 -- Preliminary results from a dose titration study showed that treatment with the fixed-dose combination therapy AZOR® (amlodipine and olmesartan medoxomil) helped the majority (cumulative 75.8 percent) of hypertensive patients to reach systolic blood pressure goals of < 140 mm Hg ( ... read more

PARSIPPANY, NJ -- (Marketwire) -- 05/01/10 -- Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg ... read more

PARSIPPANY, NJ -- (Marketwire) -- 05/13/09 -- Daiichi Sankyo, Inc. today announced that the United States Food and Drug Administration (FDA) has approved the combination treatment AZOR® (amlodipine and olmesartan medoxomil) as initial or 'first-line' therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure (BP) goals. The FDA approval ... read more

PARSIPPANY, NJ -- (Marketwire) -- 05/08/09 -- Daiichi Sankyo, Inc. announced today that data presented at the American Society of Hypertension, Inc. (ASH) Twenty-Fourth Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the AZOR® Trial Evaluating Blood Pressure Reductions and Control (AZTEC) demonstrated that a stepwise amlodipine and olmesartan medoxomil-based titration ... read more

PARSIPPANY, NJ -- (Marketwire) -- 05/08/09 -- Daiichi Sankyo, Inc. announced today that new data presented at the American Society of Hypertension, Inc. (ASH) Annual Scientific Meeting and Exposition (ASH 2009) in San Francisco from the BeniSILVER study found that BENICAR® and BENICAR HCT® provided a mean reduction in 24-hour ambulatory systolic blood ... read more